First injection to stop HIV approved

ViiV Healthcare, a GSK subsidiary, has secured NHS approval in England and Wales for its long-acting cabotegravir (CAB-LA) injection for HIV pre-exposure prophylaxis (PrEP). This approval introduces a new revenue stream, with the treatment carrying a list price of approximately £7,000 per patient annually, initially targeting around 1,000 high-risk individuals who face challenges with daily oral PrEP adherence. The six-times-a-year injection offers a crucial, more convenient alternative, potentially expanding the overall PrEP market and strengthening ViiV's competitive position in HIV prevention strategies.

Analysis

The NHS in England and Wales has approved ViiV Healthcare's long-acting cabotegravir (CAB-LA) injection for HIV pre-exposure prophylaxis (PrEP), aligning with Scotland's policy. This six-times-a-year injection provides a crucial alternative to daily oral PrEP, addressing adherence challenges for vulnerable populations. The treatment carries a list price of approximately £7,000 per patient per year, though an undisclosed NHS discount applies. This approval is a significant step towards the UK's ambition of ending new HIV cases by 2030.

Initially targeting around 1,000 high-risk individuals for whom oral PrEP is difficult, this approval expands the addressable market for HIV prevention. The convenience and discretion offered by CAB-LA are expected to improve PrEP uptake, particularly among groups with lower adherence rates, thereby addressing existing inequalities in access. This development strengthens ViiV Healthcare's competitive position in the evolving HIV prevention landscape.

While the rollout faces potential challenges regarding clinic capacity and equitable access, the long-term outlook for injectable PrEP is positive. Early results for lenacapavir, suggesting a potential annual jab, indicate continued innovation and a dynamic future in this therapeutic area, potentially further shifting market preferences.

Key Decisions for Investors

• Monitor ViiV Healthcare's (GSK) revenue growth and market penetration for CAB-LA, considering the undisclosed NHS discount and initial patient numbers.
• Evaluate the broader impact on the HIV prevention market, noting potential expansion and competitive dynamics as new long-acting PrEP options emerge.
• Assess the operational efficiency of the NHS rollout and its implications for patient access and future adoption rates, particularly for vulnerable groups.